<DOC>
	<DOC>NCT01565408</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this dose-escalating trial is to assess the safety and tolerability of multiple doses of NNC0114-0006 in subjects with rheumatoid arthritis (RA).</brief_summary>
	<brief_title>Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>A diagnosis of RA, meeting the 2010 ACREULAR (American College of RheumatologyEuropean League Against Rheumatism) or the 1987 ACR classification criteria, made at least 4 months prior to trial drug administration Active RA, characterised by a DAS28CRP equal to or above 4.5 and at least 5 tender and 5 swollen joints Methotrexate (MTX) treatment for at least 16 weeks (dose equal to or above 7.5 mg/week and equal to or below 25 mg/week) at a stable dose for at least 6 weeks prior to dosing Female subjects not pregnant and not nursing Subjects with chronic inflammatory autoimmune disease other than RA Any active or ongoing chronic infectious disease requiring systemic antiinfectious treatment within 4 weeks prior to randomisation Body mass index (BMI) below 18.0 or above 35.0 kg/m^2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>